The Clinical Deep-Dive
Evidence-based information on the targeted therapies in our catalog — mechanisms, biomarker requirements, and safety considerations.
Targeted Therapy Explained
Targeted oncology therapies are designed to interfere with specific molecular targets involved in tumor growth and progression — such as HER2, EGFR, ER, and KRAS. Unlike conventional chemotherapy, these agents aim to spare healthy tissue while blocking the pathways cancer cells rely on to survive and multiply.
Mechanism Classes
Our catalog spans several mechanism classes: selective estrogen receptor degraders (SERDs) for ER+ breast cancer, HER2 and EGFR tyrosine-kinase inhibitors, and KRAS G12C inhibitors. Each class is selected based on tumor biomarker profiling to match the right drug to the right patient.
Biomarker Testing
Before initiating any targeted therapy, confirmatory biomarker testing is required — including hormone-receptor status, HER2 amplification, and genomic sequencing for actionable mutations. Our clinical team coordinates with your oncologist to ensure results are current before dispensing.
Safety & Monitoring
All targeted therapies carry risks of adverse effects. Common monitoring includes hepatic function panels, cardiac assessment (for HER2 agents), and dermatologic surveillance. Patients should report new symptoms promptly and maintain scheduled follow-ups with their treating oncologist.